-
Tropisetron Hydrochloride: Assay Guide
2026-09-16
A scenario-based guide to using Tropisetron Hydrochloride in receptor, viability, proliferation, and transporter studies. It explains how SKU B2258 supports controlled formulation, interpretation of concentration-dependent effects, and practical vendor selection.
-
Dual SMAD and Wnt Inhibition for iPSC-RGCs
2026-09-16
Chavali et al. developed a chemically defined, non-genetic method that combines dual SMAD and canonical Wnt inhibition to generate retinal ganglion cells from induced pluripotent stem cells. The approach produced reproducible retinal progenitor and RGC populations, exceeding 80% RGC purity before CD90.2-based magnetic enrichment and supporting glaucoma-oriented disease modeling.
-
Veratridine: Voltage-Gated Sodium Channel Opener
2026-09-15
Veratridine is a voltage-gated sodium channel opener that sustains membrane depolarization by impairing sodium-channel inactivation. Its defined activity supports sodium channel dynamics research, excitotoxicity studies, seizure mechanism research, and screening assays for sodium channel blockers.
-
CGRP/SP–Piezo2 Signaling in Trigeminal Allodynia
2026-09-15
Liao et al. identify a Ca2+-dependent CGRP/SP–Piezo2 positive-feedback circuit linking trigeminal root compression, neuroinflammation, and mechanical allodynia. The study combines a rat compression model, pathway perturbation, tissue analysis, and cell-based experiments to show how ATP and PKC-associated signaling may couple trigeminal neurons with Merkel cells.
-
Eudragit S100-Coated LNPs for Oral RNA Delivery
2026-09-14
Haque, Shrestha, and Mattheolabakis developed a pH-responsive Eudragit S 100 coating for lipid nanoparticles designed to protect RNA during gastrointestinal transit. Their in vitro data show that coating preserved nucleic acid integrity in simulated gastric conditions and that phosphate treatment restored transfection activity after coating, supporting further investigation of enteric LNP systems for oral RNA delivery.
-
WNT5a/GSK3/β-Catenin Control of FAP Adipogenesis
2026-09-14
The 2020 Cell Death & Differentiation study identifies the WNT5a/GSK3/β-catenin axis as a regulatory system that restrains adipogenic conversion of skeletal muscle fibro/adipogenic progenitors. By integrating pharmacological, cytometric, transcriptomic, computational, and mouse-model evidence, the work links impaired WNT5a signaling with pathological fat accumulation and reduced regenerative support in dystrophic muscle.
-
NP-40 Lysis Buffer for Neuroimmune Workflows
2026-09-13
NP-40 Lysis Buffer enables mild, non-denaturing extraction for Western blotting, immunoprecipitation, co-immunoprecipitation, and ELISA. This workflow-oriented guide shows how to preserve signaling states and native protein complexes while adapting lysis to animal, plant, fungal, and bacterial samples.
-
Formononetin and Oxaliplatin Neurotoxicity
2026-09-12
A 2026 NeuroToxicology study identifies formononetin as a selective neuroprotective candidate against oxaliplatin-induced peripheral neurotoxicity. The work links protection of sensory neurons to Nrf2/HO-1 activation and shows that formononetin preserved anticancer activity in colorectal and cervical cancer cell models, unlike the broad antioxidant NAC.
-
Palonosetron and Chemotherapy-Induced Nausea
2026-09-11
Ruhlmann and Herrstedt’s review examines why palonosetron may differ from earlier 5-HT3 receptor antagonists, emphasizing its long half-life, high receptor affinity, allosteric binding, and positive cooperativity. Its practical implication is that antiemetic studies should distinguish acute from delayed chemotherapy-induced nausea and vomiting and evaluate whether pharmacologic differences translate into clinically meaningful benefit.
-
AL-8810 and the FP Receptor: From Signal to Translation
2026-09-11
AL-8810 offers a reversible pharmacological way to dissect PGF2α–FP receptor biology across endometrial, vascular, ocular, and smooth-muscle models. This thought-leadership framework connects receptor antagonism with HIF-1α-regulated vascular remodeling, ERK1/2 signaling, MMP-2 secretion, and translational study design.
-
Phosphatase Inhibitor Cocktail 2 in Cancer Assays
2026-09-10
Phosphatase Inhibitor Cocktail 2 helps preserve labile signaling states in tumor-cell lysates and phosphorylation-focused assays. This guide connects inhibitor chemistry with practical decisions for studying PI3K/Akt and EMT biology in canine mammary tumor models.
-
Tomivosertib Suppresses Ectopic Activity in Human DRG
2026-09-10
The reference study provides direct human-neuron evidence that MNK inhibition with tomivosertib can reversibly reduce spontaneous activity in sensory neurons obtained from patients with radiculopathy. Its combination of electrophysiology and rapid measurement of eIF4E phosphorylation supports MNK signaling as a translationally relevant target, while also highlighting the importance of studying human nociceptors directly.
-
Manufacturing LNP Size for Better mRNA Expression
2026-09-09
The reference study shows that small changes in aqueous-to-organic phase ratio during microfluidic manufacture can tune lipid nanoparticle dimensions and expose size-dependent differences in mRNA expression. Its central practical contribution is a process-to-biology framework: larger particles favored expression in HEK293 cells, whereas intermediate sizes were more robust in mice, emphasizing that LNP size must be optimized in the relevant biological model.
-
Endotoxemia, NLRP3, and Tissue Factor EVs
2026-09-09
Sachetto et al. dissected how TLR4, caspase-11, NLRP3, and caspase-1 contribute to tissue factor-positive extracellular vesicle release and coagulation during LPS-induced endotoxemia. Their time-resolved genetic and pharmacologic analysis identifies TLR4 as the dominant driver, while caspase-11 and NLRP3 make smaller, late contributions.
-
Camptothecin and Adaptive DNA Damage Assays
2026-09-08
Camptothecin is a topoisomerase I inhibitor that connects replication-associated DNA damage with apoptosis, autophagy, and adaptive mutability. This article develops a stress-state-aware assay strategy inspired by a 2026 Cell study of prion-regulated mutagenesis.